Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04848493Completed

National Project on Vaccines, COVID-19 and Frail Patients

Role: collaborator

NCT04120415Phase 2Completed

A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

Role: collaborator

NCT04791423Phase 2Completed

Study of GRAd-COV2 for the Prevention of COVID-19 in Adults

Role: collaborator

NCT04528641Phase 1Completed

Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine

Role: collaborator

NCT02972450Phase 1Terminated

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

Role: collaborator

All 5 trials loaded